Why Is Pain & Liver Disease Focused DURECT Stock Plunging Today?

Grand News Network | November 8, 2023

DURECT Corporation (NASDAQ: DRRX) released topline results from its AHFIRM Phase 2b study of larsucosterol in 307 patients with severe alcohol-associated hepatitis (AH). 

The numerical improvement in the primary endpoint of mortality or transplant at 90 days did not achieve statistical significance for either dose of larsucosterol.

Both the 30 mg and 90 mg larsucosterol doses demonstrated a clinically meaningful trend ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner

Copyright © 2024 | All rights reserved